Therapeutic efficacy of dihydroartemisinin-piperaquine and artesunate-pyronaridine combinations in the treatment of uncomplicated <i>Plasmodium falciparum</i> malaria in Ghana, 2023.

ABSTRACT:

Introduction

Malaria case management in Ghana is a key intervention within the national malaria elimination agenda. Currently, artesunate-amodiaquine (AS-AQ), artemetherlumefantrine (AL), and artesunate-pyronaridine (AP) are the first-line medicines for treating uncomplicated malaria whilst dihydroartemisinin-piperaquine (DHAP) is the second-line medicine.

Methods

This was a one-arm prospective evaluation of the clinical, parasitological and haematological responses of children (6 months to 9 years old) treated with DHAP in five (5) sentinel sites and AP in four (4) sentinel sites between August and December, 2023 using the WHO protocol on surveillance of antimalarial drug efficacy. The DHAP study was a follow-up to the baseline conducted in 2020/2021, and the AP study was t

SUBMITTER: Abuaku B 

PROVIDER: S-EPMC12821887 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature